Synchronous occurrence of medullary and papillary thyroid cancer and survival rates
Indian Journal of Cancer · 2023-10 · 60 (4) · 556-561
DOI: 10.4103/ijc.ijc_9_21 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Cancer, online erschienen am 09.06.2023. Verfasst von Elife Akgun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Yuksek Ihtisas Hospital, Kirikkale, Turkey. Hauptthemen laut MEDLINE: Carcinoma, Papillary, Thyroid Neoplasms, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Purpose
Concurrence of medullary and papillary thyroid carcinoma (MTC and PTC) represents less than 1% of all thyroid malignancies. We aimed to reveal the demographic and clinical characteristics of this rare pathology and to evaluate the effect of the same or contralateral lobular localization of these two malignancies in clinical and laboratory features. Evaluation of progression-free survival (PFS) in current pathology is one of the important features of our study.
Methods
All patients diagnosed with simultaneous MTC and PTC after thyroidectomy were evaluated retrospectively. Data on the following variables were recorded: age, gender, tumor localization (ipsilateral lobe located MTC and PTC-Group I, contralateral lobe located MTC and PTC-Group II), tumor size, cervical lymph node metastasis, distant metastasis, tumor stage, postoperative basal calcitonin, carcinoembryonic antigen, thyroglobulin (Tg), and anti-Tg values. In all our cases, since MTC progressed before PTC, progression was accepted as serum calcitonin values exceeded 150 pg/mL.
Results
Groups were formed as follows: Group I, four cases where MTC and PTC were localized in different foci in the same lobe; Group II, nine cases where they were localized in different lobes. There was only one case in which two tumors were located in the same focus. The case with dual differentiation was included in Group I (35. 7%). When the PFS of the two groups were compared, no statistically significant difference was found ( P = 0.87).
Conclusions
As a result of this analysis, the location of the simultaneously detected PTC in the same or different lobes with the MTC does not make a significant difference in clinical and laboratory features.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Yuksek Ihtisas Hospital, Kirikkale, Turkey.
- Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
- Department of Pathology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
- Department of General Surgery, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
ORCID-Profile: Elife Akgun, Sait Sager, Fatih Beytur, Azizullah Nazari, Tulin Ozturk, Serkan Teksoz, Kerim Sonmezoglu
Zitieren
APA
Akgun, E., Sager, S., Beytur, F., Nazari, A., Ozturk, T., Teksoz, S., & Sonmezoglu, K. (2023). Synchronous occurrence of medullary and papillary thyroid cancer and survival rates. Indian Journal of Cancer, 60(4), 556-561. https://doi.org/10.4103/ijc.ijc_9_21
Vancouver
Akgun E, Sager S, Beytur F, Nazari A, Ozturk T, Teksoz S, et al. Synchronous occurrence of medullary and papillary thyroid cancer and survival rates. Indian Journal of Cancer. 2023;60(4):556-561. doi:10.4103/ijc.ijc_9_21
BibTeX
@article{Akgun2023,
author = {Akgun, Elife and Sager, Sait and Beytur, Fatih and Nazari, Azizullah and Ozturk, Tulin and Teksoz, Serkan and Sonmezoglu, Kerim},
title = {Synchronous occurrence of medullary and papillary thyroid cancer and survival rates},
journal = {Indian Journal of Cancer},
year = {2023},
volume = {60},
number = {4},
pages = {556--561},
doi = {10.4103/ijc.ijc_9_21}
}
EUVIMED